Takeda inks up to $500M collaboration with extra-cellular matrix biotech for NASH
With Takeda’s mass, over-the-counter sell-off nearing completion, the Japanese drugmaker is beefing up the discovery engine it wants to be the core part of …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
